Triptolide payloads interfere with the cell's ability to make messages from its genes. An antibody-linked version has been studied in cancer cells and mice.
Y-TR1 combines the CD26-directed antibody YS110 with a triptolide derivative that inhibits the general transcription factor TFIIH. The published study reported altered RNA synthesis and antitumor activity in CD26-positive experimental models. This is preclinical evidence for a transcription-directed conjugate, not evidence that triptolide is an established antibody payload in clinical care.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Transcription-inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Transcription-inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/